Infusion codes: The confusion over infusion remains, but CMS officials clarify what constitutes a push

Why This Topic Matters

Drug administration coding changes can affect claim submission, payer interpretation, and compliance, especially when guidance is evolving. Understanding what CMS has clarified and what remains unresolved helps practices reduce billing errors and stay aligned with current payer expectations.

Article Sections

1. Overview of CMS implementation issues

   Introduces the confusion surrounding the new drug administration code structure and explains why practices are seeking clarification. Summarizes the general context of CMS implementation and pending AMA involvement.

2. CMS clarification on short infusions

   Discusses CMS guidance on how brief drug administration services are being treated for billing purposes. Addresses the broader distinction between infusion concepts and other administration categories.

3. Carrier discretion and unresolved scenarios

   Describes situations not fully addressed by the national guidance and the role of carriers in interpreting those cases. Notes that additional clarification is still pending for selected administration scenarios.

4. Biologic response modifiers and concurrent administration questions

   Covers the separate discussion involving biologic response modifiers and concurrent use with other drug administration services. Notes that this area remains under review by CMS and the CPT Editorial Panel.